NCT05466149 2025-11-19
Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion
Allist Pharmaceuticals, Inc.
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT06962865 2025-07-16
A Phase â…¡ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT03452592 2025-04-03
Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M
Allist Pharmaceuticals, Inc.
Phase 2 Terminated